In last trading session, Century Therapeutics Inc (NASDAQ:IPSC) saw 0.47 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price level of $0.60 trading at $0.04 or 6.77% at ring of the bell on the day assigns it a market valuation of $50.70M. That closing price of IPSC’s stock is at a discount of -773.33% from its 52-week high price of $5.24 and is indicating a premium of 8.33% from its 52-week low price of $0.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.42 million shares which gives us an average trading volume of 510.26K if we extend that period to 3-months.
For Century Therapeutics Inc (IPSC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.44 in the current quarter.
Century Therapeutics Inc (NASDAQ:IPSC) trade information
Upright in the green during last session for gaining 6.77%, in the last five days IPSC remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.60 price level, adding 10.31% to its value on the day. Century Therapeutics Inc’s shares saw a change of -40.96% in year-to-date performance and have moved -9.02% in past 5-day. Century Therapeutics Inc (NASDAQ:IPSC) showed a performance of -20.25% in past 30-days. Number of shares sold short was 3.41 million shares which calculate 7.13 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 88.0% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -733.33% in reaching the projected high whereas dropping to the targeted low would mean a loss of -733.33% for stock’s current value.
Century Therapeutics Inc (IPSC) estimates and forecasts
This year revenue growth is estimated to rise 49.74% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 975k for the same. And 4 analysts are in estimates of company making revenue of 475k in the next quarter. Company posted 268k and 855k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.24% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 29.75% while estimates for its earnings growth in next 5 years are of 12.88%.
Century Therapeutics Inc (NASDAQ:IPSC)’s Major holders
Insiders are in possession of 28.07% of company’s total shares while institution are holding 57.96 percent of that, with stock having share float percentage of 80.58%. Investors also watch the number of corporate investors in a company very closely, which is 57.96% institutions for Century Therapeutics Inc that are currently holding shares of the company. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC is the top institutional holder at IPSC for having 5.41 million shares of worth $13.8 million. And as of 2024-06-30, it was holding 8.6848 of the company’s outstanding shares.
The second largest institutional holder is VR ADVISER, LLC, which was holding about 5.39 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.651 of outstanding shares, having a total worth of $13.74 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.31 shares of worth $0.78 million or 1.55% of the total outstanding shares. The later fund manager was in possession of 1.08 shares on Dec 31, 2024 , making its stake of worth around $0.64 million in the company or a holder of 1.27% of company’s stock.
